

Company Announcement

Tuesday 23rd June 2009

Melbourne, Australia

Lapse and Expiry of Unlisted Share Options

Clinuvel Pharmaceuticals Ltd (the 'Company') wishes to advise in accordance to the terms and conditions of issue that the following unquoted share options have lapsed and expired.

Class	Number	Exercise price	Expiry Date
CUVAI	300,000	\$0.865	19/04/2009
CUVAO	3,400,000	\$0.86	09/02/2012
CUVAO	30,000	\$0.86	03/08/2012

Accordingly, the Company confirms there are 19,190,000 unquoted share options on issue.

End

For more information contact:

Darren Keamy

Company Secretary

Clinuvel Pharmaceuticals Limited

T: +61 3 9660 4900

E: investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, afamelanotide for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for afamelanotide can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia

T +61 3 9660 4900
F +61 3 9660 4999

www.clinuvel.com